Gene · 81607
Papers1,879
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
21 to 40 of 1,879
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Antibody-Drug Conjugates in the Treatment of Esophageal Cancer. | Curr Treat Options Oncol | 2026 | 42700288 | PubTator, text mining | PubMed |
| Coordinated Expression of ADC Targets ERBB2, TACSTD2, and NECTIN4 in Bladder Cancer: A Multi-Scale Transcriptomic and Proteomic Landscape Analysis. | Curr Issues Mol Biol | 2026 | 42651823 | PubTator, text mining | PubMed |
| Treatment Strategies for Extramammary Paget Disease: A Narrative Review of Current Status and Future Directions. | Cancers (Basel) | 2026 | 42649901 | PubTator, text mining | PubMed |
| TROP-2 and Nectin-4 Expression in Muscle-Invasive Urothelial and Rare Non-Urothelial Bladder Carcinoma: Association with Tumour Stage and Clinical Outcome. | Cancers (Basel) | 2026 | 42649895 | PubTator, text mining | PubMed |
| Spatial Transcriptomics of Micropapillary, Plasmacytoid, and Sarcomatoid Urothelial Carcinoma Reveals Distinct Molecular Landscapes. | Lab Invest | 2026 | 42641761 | PubTator, text mining | PubMed |
| SHR-A2102, a nectin-4 directed antibody-drug conjugate, in patients with pretreated advanced solid tumours: a multicentre, single-arm, phase 1 trial. | Lancet Oncol | 2026 | 42636836 | PubTator, text mining | PubMed |
| CRB-701: A Second-generation Nectin-4-Targeted Antibody-Drug Conjugate with Optimized Stability and Pharmacokinetics for the Treatment of Solid Tumors. | Cancer Res Commun | 2026 | 42636059 | PubTator, text mining | PubMed |
| Screening of potential antibody-drug conjugate (ADC) targets in neuroendocrine carcinoma of the cervix: implications for targeted therapy. | J Gynecol Oncol | 2026 | 42625475 | PubTator, text mining | PubMed |
| European Society for Medical Oncology Gynaecological Cancers Congress 2026: key scientific advances from the oral sessions. | Int J Gynecol Cancer | 2026 | 42624675 | PubTator, text mining | PubMed |
| Recurrent Invasive Clear Cell Subtype of Upper Tract Urothelial Carcinoma Responding to Enfortumab Vedotin and Pembrolizumab After Chemotherapy: A Case Report. | Arch Esp Urol | 2026 | 42608376 | PubTator, text mining | PubMed |
| Advances in NIR-II Fluorescence Laparoscopy for Precision Diagnosis and Theranostics of Urological Oncology. | Int J Nanomedicine | 2026 | 42605362 | PubTator, text mining | PubMed |
| Evaluation of HER2 and Nectin-4 Expression in Primary Vaginal Cancers. | Int J Mol Sci | 2026 | 42589670 | PubTator, text mining | PubMed |
| Peste Des Petits Ruminants Virus Infection Induces Syncytium Formation via RhoA-Rock1 Signaling Pathway to Promote Viral Replication. | Animals (Basel) | 2026 | 42589043 | PubTator, text mining | PubMed |
| Predicting Therapeutic Response to Antibody-Drug Conjugates Using Targeted PET Imaging: A Systematic Review. | Cancers (Basel) | 2026 | 42588729 | PubTator, text mining | PubMed |
NECTIN4 (PVRL4) expression in pancreatic cancer patients might be associated with a more unfavorable prognosis, independent of age at diagnosis, sex, and stage: A public microarray and RNA sequencing data based bioinformatics analysis. | Comput Biol Chem | 2026 | 42567085 | PubTator, text mining | PubMed |
| Comparative safety profiles of antibody-drug conjugates: a real-world analysis of monotherapy and combination regimens in solid tumors. | Drug Deliv | 2026 | 42557654 | PubTator, text mining | PubMed |
| Integrating AlphaFold2 with physics-based ensemble docking for high-efficiency nanobody discovery. | Chem Sci | 2026 | 42540367 | PubTator, text mining | PubMed |
| ERBB2 copy number alterations and protein expression in bladder cancer treated by cystectomy. | Hum Pathol | 2026 | 42532350 | PubTator, text mining | PubMed |
| Nectin-4 and Trop-2 expression in collecting duct carcinoma: new promising therapeutic targets. | ESMO Open | 2026 | 42526179 | PubTator, text mining | PubMed |
| Conversion to Pathological Complete Response by Enfortumab Vedotin in Metastatic Sarcomatoid Urothelial Carcinoma With Nectin-4 Expression: A Case Report. | IJU Case Rep | 2026 | 42523616 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/81607/papers?page=2